Nature Communications (Nov 2020)

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

  • Yi Bao,
  • Gokce Oguz,
  • Wee Chyan Lee,
  • Puay Leng Lee,
  • Kakaly Ghosh,
  • Jiayao Li,
  • Panpan Wang,
  • Peter E. Lobie,
  • Sidse Ehmsen,
  • Henrik J. Ditzel,
  • Andrea Wong,
  • Ern Yu Tan,
  • Soo Chin Lee,
  • Qiang Yu

DOI
https://doi.org/10.1038/s41467-020-19704-x
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 17

Abstract

Read online

Resistance to anti-HER2 therapies in breast cancer remains a significant clinical challenge. Here, the authors demonstrate that EZH2 regulates response to HER2-targeting therapies in breast cancer, in part, by modulating the expression of PPP2R2B.